StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Lagevrio (molnupiravir by Quarter

Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

QuarterlyAnnual

Merck Lagevrio (molnupiravir: -95.0% in Q2 2026, down 68.0 pts from a year earlier. That is the lowest of the 11 quarters on record here.

Latest, Q2 2026
-95.0%
Period ended Jun 30, 2026
Change on a year earlier
-68.0 pts
-27.0% in Q2 2025
History
11 quarters
Since Q1 2023
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Lagevrio | 28 | 5 | 32 | 102 | 83 | 185 | 138 | 57 | 380 | -95 | -95 | -82 | -83”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-95.0%-68.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025-53.0%-16.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025-65.0%–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025-27.0%+15.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q4 2024Dec 31, 2024-37.0%+39.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2024Jun 30, 2024-42.0%+40.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-5.0%+82.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-76.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202351.0%–Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 2023-82.0%–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 2023-87.0%–Form 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗

Cite this data

StockData. (2026). Merck Lagevrio (molnupiravir (%), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lagevrio-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.